Although the mechanism underlying p100 inhibition of PHLPP2 expression is still under investigation, p100 acting as a tumor suppressor by initiating a novel PHLPP2/CREB/miR-302d/Cyclin D1 axis in regulation of anchorage-independent growth as illustration in Figure 8, together with our new discovery of p100 suppression in bladder cancers provides significant insights into the understanding of p100 in the processes of pathology in human bladder carcinogenesis. Here, CCND1 is linked to urinary bladder carcinoma.